ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)
Sep 4, 2013 ·
5m 26s
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Information
| Author | cancerGRACE |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
